Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer

Abstract Background Several reports showed that high soluble programmed death-ligand 1(sPD-L1) level was a risk factor for poor prognosis in various tumors. To date, the clinicopathologic and prognostic impact of sPD-L1 level in patients with hepato-biliary-pancreatic cancer have not been determined. Methods A total of 119 patients (66 patients with hepatocellular carcinoma, 23 patients with cholangiocarcinoma, 30 patients with pancreatic cancer) who were treated at the Toho University Omori Hospital (Tokyo, Japan) from 2008 to 2016 were retrospectively analyzed. sPD-L1 levels were measured using an enzyme-linked immunosorbent assay for PD-L1 to evaluate clinicopathologic and prognostic impact. Results sPD-L1 levels were significantly higher in low-albumin group than normal albumin group. According to stages in hepatocellular carcinoma and cholangiocarcinoma, there were no significant differences in sPD-L1 levels, which gradually increased according to stage in pancreatic cancer. Using a cut-off value of 81.6 pg/ml for sPD-L1level, the high sPD-L1 group showed significantly worse prognosis than the low sPD-L1 group in patients with pancreatic cancer. Multivariate analysis identified sPD-L1 level ≥ 81.6 mg/dl (p = 0.047) as an independent predictor of poor overall survival in patients with pancreatic cancer. Conclusion High sPD-L1 levels were independently associated with poor prognosis. However, this association in hepatocellular carcinoma or cholangiocarcinoma was not clear.

Download Full-text

Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma

BMC Cancer ◽

10.1186/s12885-020-6612-2 ◽

2020 ◽

Vol 20 (1) ◽

Cited By ~ 2

Author(s):

Inju Cho ◽

Hansang Lee ◽

Sang Eun Yoon ◽

Kyung Ju Ryu ◽

Young Hyeh Ko ◽

...

Keyword(s):

Central Nervous System ◽

Nervous System ◽

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Serum Levels ◽

Programmed Death Ligand 1 ◽

Large B Cell Lymphoma ◽

Programmed Death ◽

Large B Cell

Download Full-text

Clinical significance of elevation of the serum IL-6 level in patients with advanced pancreatic cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.4_suppl.181 ◽

2011 ◽

Vol 29 (4_suppl) ◽

pp. 181-181

Author(s):

S. Mitsunaga ◽

M. Ikeda ◽

K. Nakachi ◽

I. Ohno ◽

S. Shimizu ◽

...

Keyword(s):

Pancreatic Cancer ◽

Tumor Volume ◽

Performance Status ◽

Advanced Pancreatic Cancer ◽

Japanese Version ◽

Serum Levels ◽

Ecog Performance Status ◽

Reactive Protein ◽

Treatment Naïve ◽

Median Change

181 Background: IL-6, one of the pro-inflammatory cytokines, is a recognized mediator of cachexia and cancer cell invasion. It has been reported that elevation of the serum IL-6 level may be associated with deterioration of the clinical condition and tumor progression in advanced pancreatic cancer (PC) patients. The aim of this study was to clarify the clinical features of increased serum IL-6 levels in patients with advanced PC receiving chemotherapy. Methods: Patients with treatment-naïve unresectable PC and no obvious infectious conditions were eligible for this study. Serum levels of IL-6 were measured by an electrochemiluminescence assay. Symptoms were rated numerically from 0 to 10 using the Japanese version of the M. D. Anderson Symptom Inventory. Tumor volume was calculated as the sum of the long diameters of the tumors. The measurements were performed before chemotherapy and at one month after the start of chemotherapy. Results: A total of 87 patients (male/female: 41/46; ECOG performance status: 0/1/2: 59/26/1; media age: 66 years) were enrolled; all patients were administered systemic chemotherapy (gemcitabine [GEM]/GEM+S-1/GEM+other/S-1: 52/11/9/15). The median serum level of IL-6 was 1.3 pg/mL before chemotherapy (at baseline) and 1.8 pg/mL at one-month after the start of chemotherapy. The median change of IL-6 from the baseline was +0.18 pg/mL. Patients with increase of the serum IL-6 level by more than 0.18 pg/mL were assigned to the elevated IL-6 group (n=42; median change in IL-6: +1.66 pg/mL). The elevated IL-6 group showed more sadness (p=0.019), numbness (p=0.008), and gain of body weight (p=0.016) at the baseline as compared to the non-IL-6-elevated group (n=42; median change in IL-6: -0.27 pg/mL). Comparison of the elevated and non-IL-6-elevated groups revealed a greater degree of increase in the tumor volume (p=0.015), deterioration of nausea (p=0.046) and vomiting (p=0.028), neutrophilia (p=0.004), and elevation of the serum C-reactive protein (p=0.011) in the elevated IL-6 group than in the non-IL-6-elevated group. Conclusions: Elevation of the serum IL-6 level may be associated withsymptom deterioration, increase of the tumor mass, and inflammatory reaction in patients with advanced PC. No significant financial relationships to disclose.

Download Full-text

Tanshinone IIA could decrease programmed death-ligand 1 expression in human pancreatic cancer cells in vitro

Annals of Oncology ◽

10.1093/annonc/mdx261.039 ◽

2017 ◽

Vol 28 ◽

pp. iii23-iii24

Author(s):

Cheng Su Chin

Keyword(s):

Pancreatic Cancer ◽

Cancer Cells ◽

Tanshinone Iia ◽

Human Pancreatic Cancer ◽

Programmed Death Ligand 1 ◽

Pancreatic Cancer Cells ◽

Programmed Death

Download Full-text

Serum levels of soluble programmed death-ligand 1 (sPD-L1): A possible biomarker in predicting post-treatment outcomes in patients with early hepatocellular carcinoma

International Immunopharmacology ◽

10.1016/j.intimp.2021.107467 ◽

2021 ◽

Vol 94 ◽

pp. 107467

Author(s):

Tudor Mocan ◽

Maria Ilies ◽

Iuliana Nenu ◽

Rares Craciun ◽

Adelina Horhat ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Treatment Outcomes ◽

Serum Levels ◽

Post Treatment ◽

Programmed Death Ligand 1 ◽

Early Hepatocellular Carcinoma ◽

Programmed Death

Download Full-text

Are preoperative high soluble programmed death ligand 1 levels responsible for patients’ poor prognoses in hepato-biliary-pancreatic cancer?

10.21203/rs.3.rs-52812/v2 ◽

2020 ◽

Author(s):

Rei Okada ◽

Yuichiro Otsuka ◽

Masaru Tsuchiya ◽

Tetsuya Maeda ◽

Jun Ishii ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Pancreatic Cancer ◽

Poor Prognosis ◽

Enzyme Linked Immunosorbent Assay ◽

Prognostic Impact ◽

Poor Overall Survival ◽

Programmed Death Ligand 1 ◽

Programmed Death ◽

Normal Albumin ◽

Worse Prognosis

Abstract Background: Several reports showed that high soluble programmed death-ligand 1(sPD-L1) level was a risk factor for poor prognosis in various tumors. To date, the clinicopathologic and prognostic impact of sPD-L1 level in patients with hepato-biliary-pancreatic cancer have not been determined. Methods: A total of 119 patients (66 patients with hepatocellular carcinoma, 23 patients with cholangiocarcinoma, 30 patients with pancreatic cancer) who were treated at the Toho University Omori Hospital (Tokyo, Japan) from 2008 to 2016 were retrospectively analyzed. sPD-L1 levels were measured using an enzyme-linked immunosorbent assay for PD-L1 to evaluate clinicopathologic and prognostic impact. Results: sPD-L1 levels were significantly higher in low-albumin group than normal albumin group. According to stages in hepatocellular carcinoma and cholangiocarcinoma, there were no significant differences in sPD-L1 levels, which gradually increased according to stage in pancreatic cancer. Using a cut-off value of 81.6pg/ml for sPD-L1level, the high sPD-L1 group showed significantly worse prognosis than the low sPD-L1 group in patients with pancreatic cancer. Multivariate analysis identified sPD-L1 level ≥ 81.6 mg/dl ( p = 0.047) as an independent predictor of poor overall survival in patients with pancreatic cancer.Conclusion: Using a cut-off value of 81.6pg/ml for sPD-L1level, high sPD-L1 levels were independently associated with poor prognosis in patients with pancreatic cancer. However, this association in hepatocellular carcinoma or cholangiocarcinoma was not clear.

Download Full-text